The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism
- 390 Downloads
Tadalafil seems to ameliorate insulin resistance and glucose homeostasis in humans. We have previously reported that tadalafil targets human skeletal muscle cells with an insulin (I)-like effect. We aim to evaluate in human fetal skeletal muscle cells after tadalafil or I: (i) expression profile of I-regulated genes dedicated to cellular energy control, glycolitic activity or microtubule formation/vesicle transport, as GLUT4, PPARγ, HK2, IRS-1, KIF1C, and KIFAP3; (ii) GLUT4, Flotillin-1, and Caveolin-1 localization, all proteins involved in energy-dependent cell trafficking; (iii) activation of I-targeted paths, as IRS-1, PKB/AKT, mTOR, P70/S6K. Free fatty acids intracellular level was measured. Sildenafil or a cGMP synthetic analog were used for comparison; PDE5 and PDE11 gene expression was evaluated in human fetal skeletal muscle cells.
RTq-PCR, PCR, western blot, free fatty acid assay commercial kit, and lipid stain non-fluorescent assay were used.
Tadalafil upregulated I-targeted investigated genes with the same temporal pattern as I (GLUT4, PPARγ, and IRS-1 at 3 h; HK2, KIF1C, KIFAP3 at 12 h), re-localized GLUT4 in cell sites positively immune-decorated for Caveolin-1 and Flotillin-1, suggesting the involvement of lipid rafts, induced specific residue phosphorylation of IRS-1/AKT/mTOR complex in association with free fatty acid de novo synthesis. Sildenafil or GMP analog did not affect GLUT4 trafficking or free fatty acid levels.
In human fetal skeletal muscle cells tadalafil likely favors energy storage by modulating lipid homeostasis via IRS-1-mediated mechanisms, involving activation of I-targeted genes and intracellular cascade related to metabolic control. Those data provide some biomolecular evidences explaining, in part, tadalafil-induced favorable control of human metabolism shown by clinical studies.
KeywordsPDE5i Tadalafil Insulin Skeletal muscle Metabolism
This report was supported by ELI Lilly ICOS Corporation, Indianapolis, USA.
This study was funded by ELI LILLY (Ex NCR H6D-IT-V015).
Compliance with ethical standards
Conflict of interest
Crescioli C declares that she has received research grants from Company ELI LILLY. All the other authors declare that they have no competing interests.
This article does not contain any studies with animals performed by any of the authors.
- 11.J.E. Ho, P. Arora, G.A. Walford, A. Ghorbani, D.P. Guanaga, B.P. Dhakal, D.I. Nathan, E.S. Buys, J.C. Florez, C. Newton-Cheh, G.D. Lewis, T.J. Wang, Effect of phosphodiesterase inhibition on insulin resistance in obese individuals. J. Am. Heart Assoc. (2014). doi: 10.1161/JAHA.114.001001
- 12.L. Di Luigi, C. Baldari, P. Sgrò, G.P. Emerenziani, M.C. Gallotta, S. Bianchini, F. Romanelli, F. Pigozzi, A. Lenzi, L. Guidetti, The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men. J. Clin. Endocrinol. Metab. (2008). doi: 10.1210/jc.2008-0847 CrossRefGoogle Scholar
- 13.L. Di Luigi, C. Baldari, F. Pigozzi, G.P. Emerenziani, M.C. Gallotta, F. Iellamo, E. Ciminelli, P. Sgrò, F. Romanelli, A. Lenzi, L. Guidetti, The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes’ VO2max, aerobic, and anaerobic thresholds in normoxia. Int. J. Sports Med. 29, 110–115 (2008)CrossRefGoogle Scholar
- 15.M. Sheffield-Moore, J.E. Wiktorowicz, K.V. Soman, C.P. Danesi, M.P. Kinsky, E.L. Dillon, K.M. Randolph, S.L. Casperson, D.C. Gore, A.M. Horstman, J.P. Lynch, B.M. Doucet, J.A. Mettler, J.W. Ryder, L.L. Ploutz-Snyder, J.W. Hsu, F. Jahoor, K. Jennings, G.R. White, S.D. McCammon, W.J. Durham, Sildenafil increases muscle protein synthesis and reduces muscle fatigue. Clin. Transl. Sci. 6, 463–468 (2013)CrossRefGoogle Scholar
- 17.C. Crescioli, N. Sturli, M. Sottili, P. Bonini, A. Lenzi, L. Di Luigi, Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells. J. Endocrinol. Invest. (2013). doi: 10.3275/9034
- 23.C. Crescioli, M. Sottili, P. Bonini, L. Cosmi, P. Chiarugi, P. Romagnani, G.B. Vannelli, M. Colletti, A.M. Isidori, M. Serio, A. Lenzi, L. Di Luigi, Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur. J. Cell Biol. 91, 139–149 (2012)CrossRefGoogle Scholar
- 24.C. Antinozzi, C. Corinaldesi, C. Giordano, A. Pisano, B. Cerbelli, S. Migliaccio, L. Di Luigi, K. Stefanantoni, G.B. Vannelli, S. Minisola, G. Valesini, V. Riccieri, A. Lenzi, C. Crescioli, Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells. J. Steroid Biochem. Mol. Biol. 167, 169–181 (2017)CrossRefGoogle Scholar
- 25.Z.W. Yu, J. Burén, S. Enerbäck, E. Nilsson, L. Samuelsson, J.W. Eriksson, Insulin can enhance GLUT4 gene expression in 3T3-F442A cells and this effect is mimicked by vanadate but counteracted by cAMP and high glucose--potential implications for insulin resistance. Biochim. Biophys. Acta 1535, 174–185 (2001)CrossRefGoogle Scholar
- 28.S. Rome, K. Clément, R. Rabasa-Lhoret, E. Loizon, C. Poitou, G.S. Barsh, J.P. Riou, M. Laville, H. Vidal, Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J. Biol. Chem. 278, 18063–18068 (2003)CrossRefGoogle Scholar
- 30.P. Gallina, M. Paganini, L. Lombardini, R. Saccardi, M. Marini, M.T. De Cristofaro, P. Pinzani, F. Salvianti, C. Crescioli, A. Di Rita., S. Bucciantini, C. Mechi, E. Sarchielli, M. Moretti, S. Piacentini, G. Gritti, A. Bosi, S. Sorbi, G. Orlandini, G.B. Vannelli, N. Di Lorenzo, Development of human striatal anlagen after transplantation in a patient with Huntington’s disease. Exp. Neurol. 213, 241–244 (2008)CrossRefGoogle Scholar
- 31.A. Aversa, M. Caprio, A. Antelmi, A. Armani, M. Brama, E.A. Greco, D. Francomano, M. Calanchini, G. Spera, L. Di Luigi, G.M. Rosano, A. Lenzi, S. Migliaccio, A. Fabbri, Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J. Sex. Med. 8, 696–704 (2011)CrossRefGoogle Scholar
- 32.S. Marchiani, L. Bonaccorsi, P. Ferruzzi, C. Crescioli, M. Muratori, L. Adorini, G. Forti, M. Maggi, E. Baldi, The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J. Cancer Res. Clin. Oncol. 132, 408–416 (2006)CrossRefGoogle Scholar
- 33.G.L. Gravina, F. Marampon, P. Muzi, A. Mancini, M. Piccolella, P. Negri-Cesi, M. Motta, A. Lenzi, E. Di Cesare, V. Tombolini, E.A. Jannini, C. Festuccia, PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocr. Relat. Cancer. (2013). doi: 10.1530/ERC-12-0240 CrossRefGoogle Scholar
- 34.L. Di Luigi, M. Sottili, C. Antinozzi, G.B. Vannelli, F. Romanelli, V. Riccieri, G. Valesini, A. Lenzi, C. Crescioli, The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One. (2013). doi: 10.1371/journal.pone.0077745 CrossRefGoogle Scholar
- 38.L. Fu, F. Li, A. Bruckbauer, Q. Cao, X. Cui, R. Wu, H. Shi, B. Xue, M.B. Zemel, Interaction between leucine and phosphodiesterase 5 inhibition in modulating insulin sensitivity and lipid metabolism. Diabetes Metab. Syndr. Obes. (2015). doi: 10.2147/DMSO.S82338
- 40.L. Sjögren, J. Olausson, L. Strindberg, R. Mobini, P. Fogelstrand, L. Mattsson Hultén, P.A. Jansson, Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial. Diabet. Med. 33, 1299–1301 (2016)CrossRefGoogle Scholar
- 53.Y.S. Oh, L.Y. Khil, K.A. Cho, S.J. Ryu, M.K. Ha, G.J. Cheon, T.S. Lee, J.W. Yoon, H.S. Jun, S.C. Park, A potential role for skeletal muscle caveolin-1 as an insulin sensitivity modulator in ageing-dependent non-obese type 2 diabetes: studies in a new mouse model. Diabetologia 51, 1025–1034 (2008)CrossRefGoogle Scholar
- 56.N. Takei, H. Nawa, mTOR signaling and its roles in normal and abnormal brain development. Front. Mol. Neurosci. (2014). doi: 10.3389/fnmol.2014.00028
- 59.L. Vadlakonda, A. Dash, M. Pasupuleti, K. Anil Kumar, P. Reddanna, The Paradox of Akt-mTOR Interactions. Front. Oncol. (2013). doi: 10.3389/fonc.2013.00165
- 78.G. Kakik, N.S. Tuzun, S. Durdagi, Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. J. Enzyme Inhib. Med. Chem. 32, 311–330 (2017)CrossRefGoogle Scholar